To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
Institute | Diagnosis and innovative treatment | Mass spectrometry | Biomarkers
Medicines and Healthcare Technologies Department of the Frédéric Joliot Institute for Life Sciences, directed by Christophe Junot, carries out research in Diagnostic and Therapeutic Innovation, in particular in the Molecular Innovation area, around four thematic axes :
It is affiliated with two LabEx: the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT) and the Laboratory of Excellence in Chemistry of Multifunctional Molecular Architectures and Materials (CHARM3AT).
In an exploratory study, a team from SPI used mass spectrometry to analyze the gut microbiota profile of Covid-19 patients and to search for signature markers of SARS-CoV-2 gut infection using functional metaproteomics. These markers could be used to follow the evolution of the disease.
The ptairMS software, developed in the framework of a collaboration led by the CEA-Joliot, allows the processing and analysis of proton transfer mass spectrometry data, an ideal method for the real-time study of volatile organic compounds (VOCs) present in exhaled breath.
Researchers at the LIAA (SPI/DMTS) show that the initial route of sensitization to a food allergen (oral, respiratory, cutaneous) directly influences the nature of immune responses at multiple sites in the body.
Researchers from the SHFJ and the DMTS have developed optimized radioligands for immunoPET imaging. The objective is to better predict the effectiveness of anti-PD1/anti-PDL1 immunotherapy used to fight certain cancers.
Researchers from the SCBM describe a hydrogen isotope labeling process that is easy to implement and whose starting point is a "simple" mixture, in a solvent, of the product to be labeled with a pre-catalyst. Explanations of this process which finds applications in many fields including drug development or medical imaging.
A consortium of researchers, led by SPI/DMTS, presents ProMetIS, a pilot study for the deep phenotyping of murine models by combining proteomic and metabolomic approaches. A significant advance for the functional characterization of genes and the development of bioinformatics integration approaches.
Researchers from the Frédéric Joliot Institute have identified ouabain and chloroquine as two selective senolytic molecules that are effective in eliminating certain senescent cells. The study has been published in the journal Aging Cell.
To carry out their activities, researchers of Medicines and Healthcare Technologies Department have access to several research platforms, two of which certified
IBiSA, within the Frédéric Joliot Institute for Life Sciences:
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.